Table 2.
Patient characteristics according to the histological subtypes.
| Histology subtype | n (%) | Median age, y, (range) | Male, n (%) | Survival | |||
|---|---|---|---|---|---|---|---|
| Median OS, m | 5-year OS | Median DSS, m | 5-year DSS | ||||
| All patients | 1,182 | 63.0 (3–97) | 732 (61.9) | 13.0 | 39.6% | 37.0 | 47.9% |
| DLBCL | 736 (62.3) | 64.0 (2–97) | 471 (63.9) | 12.0 | 38.6% | 33.0 | 46.7% |
| LPL | 11 (0.9) | 60.0 (27–88) | 4 (36.4) | 12.0 | NR | 22.0 | NR |
| ALCL | 11 (0.9) | 47.0 (23–80) | 8 (72.7) | 2.0 | NR | 2.0 | NR |
| CLL/SLL | 22 (1.9) | 66.0 (25–93) | 13 (59.1) | 53.0 | 49.5% | 58.0 | 54.5% |
| FL | 31 (2.6) | 67.0 (41–92) | 14 (45.2) | 65.0 | 58.2% | 34.0 | 69.6% |
| BL | 40 (3.4) | 34.0 (5–87) | 32 (80.0) | 52.0 | 51.8% | 69.0 | 57.3% |
| MALT | 44 (3.7) | 66.0 (44–88) | 24 (54.5) | 109.0 | 57.3% | 153.0 | 67.2% |
| T cell lymphoma | 30 (2.5) | 59.0 (21–92) | 20 (66.7) | 8.0 | 34.7% | 11.0 | 69.1% |
| NHL-NOS | 129 (10.9) | 62.0 (13–93) | 75 (58.1) | 8.0 | 33.4% | 11.0 | 41.1% |
| HL | 27 (2.3) | 66.0 (31–90) | 14 (51.9) | 71.o | 51.5% | 85.0 | 60.1% |
| Others | 101 | 64.0 (11–94) | 57 (56.4) | 5.0 | 32.5% | 7.0 | 38.9% |
n, number of cases; y, year; m, month; OS, overall survival; DSS, disease-specific survival; NHL, non–Hodgkin lymphoma; NOS, not otherwise specified; NR, not reached; DLBCL, diffuse large B cell lymphoma; FL, Follicular lymphoma, BL, Burkitt's lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; LPL, Lymphoplasmacytic lymphoma; ALCL, Anaplastic large cell lymphoma; MALT, Mucosal-associated lymphoid tissue.